Klinikum rechts der Isar der TU München, Munich, Bayern, Germany
This dose-escalating phase I trial assesses for the first time the safety, the side effects
and the harmlessness, as well as the therapeutical benefit of the new study drug GEM3PSCA in
patients with prostate stem cell antigen (PSCA) expressing cancer types which failed to
respond to standard therapy.